Market news

WSW, NY, September 22nd, 2026, FinanceWireOn September 22, MediWound disclosed that the Department of War had added to a program it has been backing since long before most investors had heard of the company. What it

Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification DSMB did not identify safety concerns in pre-specified review; interim assessment and enrollment completion remain on track for end of the first quarter of 2027 YAVNE, Israel, September 14, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the independent Data and Safety Monitoring Board (DSMB)

MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference YAVNE, Israel, September 2, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will take place September 14–16, 2026, at the Lotte New York Palace Hotel in New York City. The f

Detailed price information for Mediwound Ltd Ord Sh (MDWD-Q) from The Globe and Mail including charting and trades.

Moby summary of MediWound Ltd.'s Q2 2026 earnings call

MediWound Ltd (MDWD) reaffirms 2026 guidance with record NexoBrid quarterly sales, advances EscharEx Phase 3 trial, and expands market opportunity to $1.05 billion in peak annual sales.

MediWound (MDWD) delivered earnings and revenue surprises of -1.32% and +19.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

EscharEx® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027 Master Services Agreement Signed with Vericel Under its BARDA Contract for NexoBrid® Second Quarter Revenue of $3.1 Million; Full-Year 2026 Revenue Guidance of $24–26 Million Reaffirmed Conference Call Today at 8:30 a.m. Eastern Time YAVNE, Israel, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics fo

MediWound (NASDAQ:MDWD) reported second-quarter 2026 revenue of $3.1 million, down from $5.7 million a year earlier, as the company continued investing in its Phase III EscharEx chronic-wound program and expanded development work around its NexoBrid burn treatment. Chief Executive Officer Ofer Gone

MediWound to Report Second Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Thursday, August 13 at 8:30 a.m. Eastern Time YAVNE, Israel, July 29, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the second quarter ended June 30, 2026, on Thursday, August 13, 2026. On the same day, MediWound’s management will host a conference call and live webc

Detailed price information for Check Point Software (CHKP-Q) from The Globe and Mail including charting and trades.

WSW, NY, July 16th, 2026, FinanceWireCathie Wood's ARK Invest is best known for its high-profile technology bets, from electric vehicles to crypto. ARK made its name investing in big names, including, amongst